In T1D, the addition of pramlintide to meal-time insulin for 29 weeks reduced postprandial hyperglycemia, body weight, and daily insulin dose by 60%, 1.3 kg, and 28%, respectively (387), and improved oxidative stress (388). Here, INS is linked to Hyperglycemia.